Breaking News

AAIPharma Completes Parenteral Facility Expansion

By Kristin Brooks | January 13, 2014

Doubles sterile development and production capacity

AAIPharma Services Corp. has completed a multi-million dollar expansion of its cGMP parenteral manufacturing facility in Charleston, SC. The expansion includes three new suites designed and built by AES Clean Technology, and equipped with a Chase-Logeman monoblock FSAS, Lytzen ISO Class 5 depyrogenation oven, BMT Steripro cGMP steam sterilizer, and SP Hull pilot-scale lyophilizer with a production-scale lyophilizer, both with ControLyo technology.
 
AAIPharma doubled the facility’s sterile product development and production capacity and added redundancies to its major processing equipment. Validation is underway and the new suites will be fully operational by February 2014. Also, the new production-scale lyophilizer will more than triple the facility’s lyophilization capacity by late 2014.
 
“Some exciting features of the expansion include low line loss and in-line weight check capabilities, which are extremely important to our clients with high-value active pharmaceutical ingredients,” said James Fife, senior director of parenteral operations. “In the coming months, the pilot and production-scale SP Hull lyophilizers will be brought online affording seamless lyophilization cycle optimization and scale-up.”

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important